Download PDF
Klin Monbl Augenheilkd 2010; 227(2): R15-R28
DOI: 10.1055/s-0029-1240867
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Neovaskularisationsglaukom

R. A. Widder1 , K.-D. Lemmen1 , T. S. Dietlein2
  • 1Augenklinik des St. Martinus-Krankenhauses, Düsseldorf
  • 2Zentrum für Augenheilkunde der Universität zu Köln
Further Information

Publication History

Publication Date:
12 February 2010 (online)

Also available at
    Permissions and Reprints

Einleitung

Neovaskularisationsglaukome sind eine große Herausforderung. Sie treten meist im Spätstadium einer Vielzahl von Gefäßerkrankungen der Netzhaut auf, die als gemeinsame Endstrecke eine ischämisch-proliferative Retinopathie entwickelt haben. Ihre Prognose ist ernst, immerhin erfolgen 12–15 Prozent aller Enukleationen wegen eines neovaskulären Glaukoms [4].

Entsprechend vielfältig sind die Anforderungen an eine effektive Behandlung, die ein optimiertes Patientenmanagement an der Schnittstelle zwischen Glaukomatologie und Retinologie erfordert:

Wie können derartige Verläufe frühzeitig erkannt und ihre Komplikationen vermieden werden? Welche drucksenkenden Konzepte (medikamentöse Glaukomtherapie, zyklodestruktive Glaukomchirurgie, filtrierende Glaukomchirurgie, Drainage-Implantate) sind bei diesen speziellen Patienten anwendbar? Welche retinologischen Behandlungskonzepte (panretinale Laserkoagulation, intravitreale oder intrakamerale Injektionen, Pars-plana-Vitrektomie) müssen primär durchgeführt oder parallel eingeleitet werden?

Literatur

  • 1 The Diabetic Retinopathy Study Research Group . Indications for photocoagulation treatment of diabetic retinopathy.  Int Ophthalmol Clin. 1987;  27 239-253
    CrossrefPubMedSearch in Google Scholar
  • 2 The Central Vein Occlusion Study Group . Natural history and clinical management of central retinal vein occlusion.  Arch Ophthalmol. 1997;  115 486-491
    PubMedSearch in Google Scholar
  • 3 Macugen Retinopathy Diabetic Study Group . Changes in retinal neovascularisation after pegaptanib (macugen) therapy in diabetic individuals.  Ophthalmology. 2006;  113 23-28
    CrossrefPubMedSearch in Google Scholar
  • 4 Agostini H J, Funk J. Neovaskuläres Glaukom. Schlote TRJ Sekundärglaukome. Stuttgart; Schattauer 2004: 237-248
    PubMedSearch in Google Scholar
  • 5 Aiello L P, Avery R L, Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
    CrossrefPubMedSearch in Google Scholar
  • 6 Arevalo J F, Wu L, Sanchez J G et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.  Eye. 2009;  23 117-123
    CrossrefPubMedSearch in Google Scholar
  • 7 Brown G C, Magargal L E, Schachat A et al. Neovascular glaucoma. Etiologic considerations.  Ophthalmology. 1984;  91 315-320
    PubMedSearch in Google Scholar
  • 8 Brown G C, Shah H G, Magargal L E et al. Central retinal vein obstruction and carotid artery disease.  Ophthalmology. 1984;  91 1627-1633
    PubMedSearch in Google Scholar
  • 9 Brown G C, Brown M M. The ocular ischemic syndrome. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 519-527
    PubMedSearch in Google Scholar
  • 10 Browning D J, Scott A Q, Peterson C B et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.  Ophthalmology. 1998;  105 776-784
    CrossrefPubMedSearch in Google Scholar
  • 11 Burton M G Z. Retinal artery occlusion. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 507-518
    PubMedSearch in Google Scholar
  • 12 Caprioli J, Strang S L, Spaeth G L et al. Cyclocryotherapy in the treatment of advanced glaucoma.  Ophthalmology. 1985;  92 947-954
    PubMedSearch in Google Scholar
  • 13 Dietlein T S, Hermann M M, Jordan J F. The medical and surgical treatment of glaucoma.  Dtsch Arztebl Int. 2009;  106 597-605 quiz 606
    PubMedSearch in Google Scholar
  • 14 Eid T E, Katz L J, Spaeth G L et al. Tube-shunt surgery versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma.  Ophthalmology. 1997;  104 1692-1700
    PubMedSearch in Google Scholar
  • 15 Eid T M, Radwan A, el-Manawy W et al. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.  Can J Ophthalmol. 2009;  44 451-456
    CrossrefPubMedSearch in Google Scholar
  • 16 Fakhraie G, Katz L, Prasad A et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.  Journal of Glaucoma. 2009;  , Epub ahead of print
    PubMedSearch in Google Scholar
  • 17 Falavarjani K, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.  Eye. 2009;  , Epub ahead of print
    PubMedSearch in Google Scholar
  • 18 Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis.  Am J Ophthalmol. 2006;  142 158-160
    CrossrefPubMedSearch in Google Scholar
  • 19 Grover S, Gupta S, Sharma R et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.  Br J Ophthalmol. 2009;  93 273-274
    CrossrefPubMedSearch in Google Scholar
  • 20 Iliev M E, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.  Am J Ophthalmol. 2006;  142 1054-1056
    CrossrefPubMedSearch in Google Scholar
  • 21 Joussen A M, Adamis A P. Inflammation as a stimulus for vascular leakage and proliferation. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 97-107
    PubMedSearch in Google Scholar
  • 22 Katz G J, Higginbotham E J, Lichter P R et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up.  Ophthalmology. 1995;  102 1263-1269
    PubMedSearch in Google Scholar
  • 23 Lang G E. Laser treatment of diabetic retinopathy.  Dev Ophthalmol. 2007;  39 48-68
    PubMedSearch in Google Scholar
  • 24 Lim T H, Bae S H, Cho Y J et al. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.  Korean J Ophthalmol. 2009;  23 188-192
    CrossrefPubMedSearch in Google Scholar
  • 25 Lin S C. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma.  J Glaucoma. 2008;  17 238-247
    CrossrefPubMedSearch in Google Scholar
  • 26 Madsen P H. Haemorrhagic glaucoma. Comparative study in diabetic and nondiabetic patients.  Br J Ophthalmol. 1971;  55 444-450
    CrossrefPubMedSearch in Google Scholar
  • 27 Mason J O, Albert M A, Mays A et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.  Retina. 2006;  26 839-841
    CrossrefPubMedSearch in Google Scholar
  • 28 Matsuyama K, Ogata N, Jo N et al. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.  Jpn J Ophthalmol. 2009;  53 243-248
    CrossrefPubMedSearch in Google Scholar
  • 29 Mermoud A, Salmon J F, Alexander P et al. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome.  Ophthalmology. 1993;  100 897-902
    PubMedSearch in Google Scholar
  • 30 Mizener J B, Podhajsky P, Hayreh S S. Ocular ischemic syndrome.  Ophthalmology. 1997;  104 859-864
    PubMedSearch in Google Scholar
  • 31 Molteno A C, Haddad P J. The visual outcome in cases of neovascular glaucoma.  Aust N Z J Ophthalmol. 1985;  13 329-335
    CrossrefPubMedSearch in Google Scholar
  • 32 Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation.  Graefes Arch Clin Exp Ophthalmol. 1994;  232 199-204
    CrossrefPubMedSearch in Google Scholar
  • 33 Ohrt V. The frequency of rubeosis iridis in diabetic patients.  Acta Ophthalmol (Copenh). 1971;  49 301-307
    PubMedSearch in Google Scholar
  • 34 Oshima Y, Sakaguchi H, Gomi F et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.  Am J Ophthalmol. 2006;  142 155-158
    CrossrefPubMedSearch in Google Scholar
  • 35 Rüfer F, Roider J. General concepts in laser treatment for retinal vascular disease. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 3309-3341
    PubMedSearch in Google Scholar
  • 36 Saito Y, Higashide T, Takeda H et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.  Acta Ophthalmol. 2009;  , Epub ahead of print
    PubMedSearch in Google Scholar
  • 37 Schlote T, Bartz-Schmidt K U. Treatment of rubeotic secondary glaucoma. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 274-282
    PubMedSearch in Google Scholar
  • 38 Scott I U, Alexandrakis G, Flynn H W et al. Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma.  Am J Ophthalmol. 2000;  129 334-341
    CrossrefPubMedSearch in Google Scholar
  • 39 Shields M B, Shields S E. Noncontact transscleral Nd:YAG cyclophotocoagulation: a long-term follow-up of 500 patients.  Trans Am Ophthalmol Soc. 1994;  92 271-287
    PubMedSearch in Google Scholar
  • 40 Shin J P, Lee J W, Sohn B J, Kim H K et al. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with ahmed valve implantation.  J Glaucoma. 2009;  18 589-594
    CrossrefPubMedSearch in Google Scholar
  • 41 Sidoti P A, Dunphy T R, Baerveldt G et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma.  Ophthalmology. 1995;  102 1107-1118
    PubMedSearch in Google Scholar
  • 42 Sivak-Callcott J A, O'Day D M, Gass J D et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.  Ophthalmology. 2001;  108 1767-1776 quiz 1777 1800
    CrossrefPubMedSearch in Google Scholar
  • 43 Takihara Y, Inatani M, Fukushima M et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.  Am J Ophthalmol. 2009;  147 912-918
    CrossrefPubMedSearch in Google Scholar
  • 44 Tsai J C, Feuer W J, Parrish R K et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.  Ophthalmology. 1995;  102 887-893
    PubMedSearch in Google Scholar
  • 45 Tsai J C, Wand M. Neovascular glaucoma. Albert AM, Miller J Principles and practice of ophthalmology. Philadelphia; Elsevier 2008: 2689-2712
    PubMedSearch in Google Scholar
  • 46 Uram M. Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma.  Ophthalmologie. 1992;  99 1823-1828
    PubMedSearch in Google Scholar
  • 47 Vasudev D, Blair M P, Galasso J et al. Intravitreal bevacizumab for neovascular glaucoma.  J Ocul Pharmacol Ther. 2009;  25 453-458
    CrossrefPubMedSearch in Google Scholar
  • 48 Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.  Ophthalmologie. 2008;  115 1571-1580
    CrossrefPubMedSearch in Google Scholar
  • 49 Yazdani S, Hendi K, Pakravan M et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.  J Glaucoma. 2009;  18 632-637
    CrossrefPubMedSearch in Google Scholar
  • 50 Yildirim N, Yalvac I S, Sahin A et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up.  J Glaucoma. 2009;  18 192-196
    CrossrefPubMedSearch in Google Scholar

Priv.-Doz. Dr. med. Randolf A. Widder

Augenklinik St. Martinus-Krankenhaus

Gladbacher Straße 26

40219 Düsseldorf

Email: r.widder@martinus-duesseldorf.de